Can you eliminate guilt by taking fake drugs?
By UNIVERSITY OF BASEL
Guilt is an emotional response that arises when an individual perceives that they have violated a moral or ethical standard.
It is often accompanied by feelings
of remorse, shame, and regret. While guilt can be a powerful motivator for
making amends and changing behavior, excessive or prolonged guilt can lead to
negative outcomes such as anxiety, depression, and reduced self-esteem.
In our interactions with others, we may not always behave in an ideal manner. When we realize that our actions have caused harm, we often experience feelings of guilt. This unpleasant feeling drives us to take corrective action, such as offering an apology or accepting responsibility.
This is why guilt is viewed as a significant moral emotion, as long as it serves an adaptive purpose – meaning it is appropriate and proportional to the situation.
“It can improve interpersonal relationships and is therefore valuable for social cohesion,” says Dilan Sezer, a researcher at the Division of Clinical Psychology and Psychotherapy at the University of Basel.
Whether
feelings of guilt can be reduced by taking placebos is something that
researchers at the Faculty of Psychology at the University of Basel have been
exploring. Their findings have now been published in the journal Scientific
Reports.
Open-label
placebos work
In order
to arouse feelings of guilt, test subjects in the study were asked to write
about a time when they had disregarded important rules of conduct, or treated
someone close to them unfairly, hurt, or even harmed them. The idea was that
the study participants should still feel bad about the chosen situation.
Participants were then randomized to three conditions: Participants in one group were given placebo pills with being deceptively told that this was a real medication while participants in another group were told that they are given a placebo.
Both
groups were told that what they had been given will be effective against
feelings of guilt. The control group was given no treatment at all. The results
showed that feelings of guilt were significantly reduced in both placebo groups
compared with those without medication.
This was
also the case when the subjects knew they had been given a placebo. “Our study,
therefore, supports the intriguing finding that placebos work even when they
are administered openly, and that explanation of the treatment is key to its
effectiveness,” states the study’s lead author, Dilan Sezer. Participants in
this study were all healthy, had no psychiatric disorders, and were not being
treated with psychotropics.
Clinical
applicability not yet proven
Where
feelings of guilt are irrational and continue for longer periods of time, they
are considered maladaptive – in other words, disproportionate. These emotions
can affect people’s health and are also, among other things, a common symptom
of depression.
Scientific studies have shown that placebo effects can be powerful in treating depression. But the finding that open-label placebos can also be useful for such strong emotions as guilt is new. It stands to reason, says Dilan Sezer, that we should try to harness these effects to help those affected.
“The administering of open-label placebos, in particular, is a promising approach, as it preserves patient autonomy by allowing patients to be fully aware of how the intervention works.”
The results of the study are an initial promising step in the direction
of symptom-specific and more ethical treatments for psychological complaints
using open-label placebos, Sezer continues.
Further research will need to be done into whether it is possible to treat maladaptive guilt with placebos. And it is still not known whether similar effects are also possible with other feeling states.
For Dilan Sezer, one thing is certain:
“Using open-label placebos would be an inexpensive and straightforward
treatment option for many psychological and physical complaints.”
Reference:
“Deceptive and open-label placebo effects in experimentally induced guilt: a
randomized controlled trial in healthy subjects” by Dilan Sezer, Cosima Locher,
and Jens Gaab, 8 December 2022, Scientific Reports.
DOI: 10.1038/s41598-022-25446-1